Pfizer Receives CHMP Backing On EU Bevacizumab And Withdraws Skinny Label Adalimumab UPDATED

 
• By Dean Rudge
Capsule
CHMP backs a biosimilar, a generic and a hybrid medicine apiece • Source: Shutterstock

More from Biosimilars

More from Products